Nature Communications (Nov 2017)
A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
- Fangfei Li,
- Jun Lu,
- Jin Liu,
- Chao Liang,
- Maolin Wang,
- Luyao Wang,
- Defang Li,
- Houzong Yao,
- Qiulong Zhang,
- Jia Wen,
- Zong-Kang Zhang,
- Jie Li,
- Quanxia Lv,
- Xiaojuan He,
- Baosheng Guo,
- Daogang Guan,
- Yuanyuan Yu,
- Lei Dang,
- Xiaohao Wu,
- Yongshu Li,
- Guofen Chen,
- Feng Jiang,
- Shiguo Sun,
- Bao-Ting Zhang,
- Aiping Lu,
- Ge Zhang
Affiliations
- Fangfei Li
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Jun Lu
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Jin Liu
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Chao Liang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Maolin Wang
- Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University
- Luyao Wang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Defang Li
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Houzong Yao
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Qiulong Zhang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Jia Wen
- College of Science, Northwest Agriculture and Forestry University
- Zong-Kang Zhang
- School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong
- Jie Li
- School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong
- Quanxia Lv
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Xiaojuan He
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Baosheng Guo
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Daogang Guan
- Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University
- Yuanyuan Yu
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Lei Dang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Xiaohao Wu
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Yongshu Li
- Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University
- Guofen Chen
- Department of Orthopaedics and Traumatology, Nanfang Hospital
- Feng Jiang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Shiguo Sun
- College of Science, Northwest Agriculture and Forestry University
- Bao-Ting Zhang
- School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong
- Aiping Lu
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- Ge Zhang
- Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University
- DOI
- https://doi.org/10.1038/s41467-017-01565-6
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Paclitaxel, a first line chemotherapeutic drug, suffers from poor water solubility and low tissue selectivity. Here, the authors report a water-soluble nucleolin aptamer-paclitaxel conjugate that selectively accumulates in ovarian tumor issues displaying reduced toxicity and improved activity profiles.
